During the corresponding time, Scilex Holding Company saw a revenue deteriorated by -22.78 % year on year, sequentially revenue fell by -11.27 %. While revenue at the Scilex Holding Company's corporate clients
Scilex Holding's Comment on Sales, Marketing and Customers
The company is developing and commercializing SEMDEXA, a novel epidural injection intended for the treatment of sciatica, targeting patients who currently use off-label corticosteroid epidural injectable products. SEMDEXA is designed to address safety concerns associated with existing treatments. The company is also developing SP-103, a triple-strength lidocaine topical system for acute pain, particularly acute low back pain (LBP) associated with muscle spasms, which has received FDA Fast Track designation for this indication. Additionally, SP-104 is under development for the treatment of fibromyalgia, a condition with limited effective approved therapies. The company serves markets including patients with sciatica, acute pain (especially acute LBP), and fibromyalgia. The product ZTlido is also referenced in company filings.
In a bold move to protect its shareholders and maintain integrity in the market, Scilex Holding Company has sent official letters to both the U.S. Securities and Exchange Commission (SEC) and the Financial Industry Regulatory Authority (FINRA), highlighting the illegal manipulation of its common stock. As an innovative revenue-generating company focused on non-opioid pain management products, Scilex is determined to expose and combat any fraudulent activities that hinder the company s growth and damage investor confidence.Scilex Holding Company, traded on the Nasdaq under the ticker symbol SCLX, is recognized for its commitment to acquiring, developing, and commercializing advanced pain management solutions ...
Scilex Holding Company, an innovative firm focused on acquiring, developing, and commercializing non-opioid pain management products, has declared the end of a Paragraph IV patent infringement lawsuit that Takeda Pharmaceuticals U.S.A., Inc. and Takeda Pharmaceuticals Company LTD (collectively, Takeda) had lodged against them. The announcement came after the U.S. Department of Justice and the U.S. Federal Trade Commission’s 45-day review period expired without any objections towards the Settlement Agreement.This legal tussle had its beginnings in Scilex’s decision to file for a revised label for its FDA-approved liquid colchicine product, Gloperba. This medication, currently used as a preventative treatm...
The pharmaceutical landscape has been gifted a breath of fresh air as Scilex Holding Company, an entity notorious for its dedicated investment in acquiring, developing, and commercializing non-opioid pain management products, launched its co-pay programs for two non-opioid pain management products, ZTlido and ELYXYB. The innovative step announced on April 9, 2024, aims to improve patient access and make treatments more affordable to patients across the United States, focusing primarily on those who are commercially insured. Scilex is taking solid strides in the fight against acute and chronic pain management, ensuring that treatments are not just effective but also accessible. In the recently announced co-pa...
Palo Alto, Calif., December 15, 2023 Scilex Holding Company (Nasdaq: SCLX, Scilex, or the Company), a trailblazer in the medical industry whose primary focus lies in the acquisition, development, and commercialization of non-opioid pain management products, has announced an extensive pharmacy initiative. This initiative involves a leading national pharmacy chain planning to stock Scilex s leading product, ELYXYB, across most of their retail locations throughout the United States. Scilex is renowned for its dedication to non-opioid treatment options that help manage acute and chronic pain. ELYXYB, a groundbreaking product from its portfolio, encapsulates this mission. In recent times, Scilex ...
Scilex Holding Company, a leading player in the non-opioid pain management industry, has taken a significant step towards expanding access to its flagship product, ELYXYB. In a recent announcement, Scilex revealed that it has signed an insurance coverage agreement with one of the top three national Pharmacy Benefit Managers (PBMs) for their Medicare population. This agreement holds the potential to greatly enhance the coverage of ELYXYB, opening doors for a wider patient base and increasing market adoption. ELYXYB is a breakthrough pain management solution that tackles acute and chronic pain without the risks associated with opioids. As the nation struggles with an opioid crisis, the demand for...
Scilex Holding Company s ZTlido Added as Preferred Agent to Tennessee s Medicaid Drug List, Enhancing Patient Access Scilex Holding Company, a leading player in non-opioid pain management products, has recently announced that its innovative lidocaine topical system, ZTlido, has been included as a preferred agent on the Medicaid Preferred Drug List (PDL) of the State of Tennessee. Effective from October 1, 2023, this development has the potential to significantly improve access to ZTlido for approximately 1.5 million adult patients aged 19 to 64. The addition of ZTlido to Tennessee s Medicaid PDL reflects the growing recognition of the effectiveness and benefits offered by the non-opioid solution...
Introduction In a significant move towards revolutionizing non-opioid pain management, Scilex Holding Company has recently announced its pharmacy initiative to stock ELYXYB in over 500 stores of a leading pharmacy chain in the U.S. This strategic collaboration aims to provide better accessibility to ELYXYB, a groundbreaking pain management product developed by Scilex. Moreover, Scilex is actively engaged in negotiating similar agreements with other major pharmacy chains, highlighting its commitment to transforming pain management practices across the nation. The Opioid Crisis and the Need for Alternative Solutions The United States continues to grapple with a devastating opioid crisis that h...
Scilex Holding Company Set to Launch FDA-Approved Gloperba in the U.S. in Q1 2024 In an exciting development, Scilex Holding Company has announced the completion of commercial manufacturing of their groundbreaking product, Gloperba. Known for their focus on non-opioid pain management products, Scilex Holding Company has successfully acquired, developed, and now commercialized a prophylactic treatment for painful gout flares in adults. With the brand marketed and distributed under Scilex Pharmaceuticals, Inc., Gloperba is expected to be launched in the United States in the first quarter of 2024. Scilex Holding Company, a revenue-generating company based in Palo Alto, California, has demonstrated ...
Scilex Holding’s Comment on Sales, Marketing and Customers
The company is developing and commercializing SEMDEXA, a novel epidural injection intended for the treatment of sciatica, targeting patients who currently use off-label corticosteroid epidural injectable products. SEMDEXA is designed to address safety concerns associated with existing treatments. The company is also developing SP-103, a triple-strength lidocaine topical system for acute pain, particularly acute low back pain (LBP) associated with muscle spasms, which has received FDA Fast Track designation for this indication. Additionally, SP-104 is under development for the treatment of fibromyalgia, a condition with limited effective approved therapies. The company serves markets including patients with sciatica, acute pain (especially acute LBP), and fibromyalgia. The product ZTlido is also referenced in company filings.
Sources:
Scilex Holding Company’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Scilex Holding Company’s corporate clients.
For your research, we’ve provided 9 tables on Scilex Holding Company corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
